A prospective randomized controlled study of multi-intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure and reduced ejection fraction (PRIME-HFrEF) trial: Rationale and design
The PRIME-HFrEF study is designed to shed new light on multiple UC-MSC administration regimens for heart failure treatment.
Authors
- Rongzhen Zhang (ORCID: https://orcid.org/0000-0001-6078-0174)
- Wenwen Jia (ORCID: https://orcid.org/0000-0001-5969-3751)
- Hu Ha (ORCID: https://orcid.org/0000-0002-9714-9324)
- Zhongmin Liu (ORCID: https://orcid.org/0000-0003-4709-4027)
- Wei Han (ORCID: https://orcid.org/0009-0002-0078-2105)
- Yuanfeng Xin (ORCID: https://orcid.org/0000-0002-0406-3530)
- Xin Gong (ORCID: https://orcid.org/0000-0002-7711-0166)
- Yuheng Jiao
- Jun Zhao
Institutions
- Shanghai East Hospital (CN)
Publication Details
- Journal
- Contemporary Clinical Trials Communications
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1016/j.conctc.2024.101350
- Citations
- 3
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 1.31
Funders
- Health and Family Planning Committee of Pudong New Area
- Shanghai Pudong New Area Health Commission
- Opening Project of Shanghai Key Laboratory of New Drug Design
- Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning